ClinicalTrials.gg
Not yet recruitingNCT07356661EPIFEEDUpdated Jan 21, 2026

Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients

An interventional study of Neurofeedback and Sham-NFB in Epilepsy and Drug Resistant Epilepsy, sponsored by Assistance Publique Hopitaux De Marseille. Not yet recruiting. Open to participants aged 18 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.

Primary conditionDrug Resistant EpilepsyRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Drug Resistant Epilepsy
Why
  1. The study's listed conditions name Drug Resistant Epilepsy, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 18 Years
Sex
All
01

Study summary

A large proportion of patients (approximately 30%) with drug-resistant epilepsy are not eligible for surgical treatment. The alternatives that can be offered to reduce the frequency of seizures are neuromodulation (vagus nerve stimulation (VNS), deep brain stimulation (DBS), or transcranial direct current stimulation (tDCS)). Most of these alternatives require invasive procedures and therefore carry risks.

Neurofeedback (NFB) is a potential adjunctive treatment that allows patients to self-modulate brain activity and thus reduce seizure frequency in a non-invasive manner.

This technique involves measuring neurophysiological activity using a technical interface to extract a parameter of interest, which is presented in real time to the participant, who has been trained and has learned how to modify it.

NFB is of interest in various neurological and psychiatric diseases and can lead to improvement in mood disorders, which are frequently associated with epilepsy. Previous NFB methods in epilepsy aimed to modulate sensorimotor rhythms or slow cortical potentials. The investigators propose an innovative EEG-NFB paradigm based on real-time estimation of EEG functional connectivity (FC) measured on the scalp EEG (NFC-FC).

This paradigm was developed based on previous studies demonstrating increased functional brain connectivity during the interictal period and decreased synchrony induced by VNS and transcranial electrical stimulation as a possible anti-epileptic mechanism.

This study consists of a randomized, double-blind comparison between NFB-FC and sham-NFB (control). The effect of this functional connectivity-based NeuroFeedBack (NFB-FC) will be evaluated on the number of seizures before and after treatment, as well as on their severity and on criteria related to quality of life.

In this study, two healthy volunteers will be recruited in order to generate the sham sessions.

02

Conditions studied

  • Epilepsy
  • Drug Resistant Epilepsy

Browse trials for

Keywords

  • epilepsy
  • neurofeedback
  • connectivity
03

In context

Drug Resistant Epilepsy Reclassified

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

This study's planned enrollment of 22 is below the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.

Browse Drug Resistant Epilepsy studies →

Lead sponsor

Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.

Compared within Drug Resistant Epilepsy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

For patients :

Inclusion Criteria:

  • Male or female patient between 18 and 65 years old
  • Patient suffering from focal or multifocal drug-resistant epilepsy
  • Patient having a number of seizures: at least 3 / month during the baseline
  • Patient's IQ, which in the investigator's opinion will enable questionnaires and neuropsychological assessments to be carried out;
  • Patient having stable medications for epilepsy 4 weeks before the baseline (except rescue treatment);
  • Patient able to understand, speak and write in French;
  • Patient willing to participate, and gave written consent to the study after receiving clear information
  • Patient beneficiary or affiliated to a health insurance plan

Exclusion Criteria:

  • - Difficulty reading or understanding the French language or inability to understand information about the study
  • Generalized epilepsy
  • Major visual impairment incompatible with the realization of neurofeedback, based on investigator's opinion.
  • Patient currently having psychogenic non-epileptic seizures
  • Any condition that makes the study subject, in the opinion of the investigator, unsuitable for the study including presence of any disease, abnormality, medical or physical condition that, in the opinion of the investigator, may adversely impact, compromise, interfere, limit, affect or reduce the safety of the subject, the integrity of the data ; Person protected by articles L1121-5, L1121-6 of Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent, person under judicial safeguard (article L1122-2)).

For healthy volunteers :

Inclusion criteria :

  • Male or female of over 18 years of age
  • IQ compatible with the realization of the study
  • Patient able to understand, speak and write in French;
  • Patient willing to participate, and gave written consent to the study after receiving clear information
  • Subject beneficiary or affiliated to a health insurance plan

Exclusion criteria :

  • Subject presenting any neurological or psychiatric illnesses.
  • Subject having major visual impairment incompatible with the realization of neurofeedback, based on investigator's opinion.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    NFB-FC

    Procedure: Neurofeedback

  • Placebo comparator
    Sham-NFB

    Procedure: Sham-NFB

Interventions

  • ProcedureNeurofeedback

    The intervention will consist of 12 training sessions at the hospital conducted with the assistance of a nurse. Each session will last approximately 40 minutes, with two resting EEG phases at the beginning and end of the session. The NFB procedure will consist of 6 training blocks of 75 seconds separated by 15-second rest blocks and 15-second baseline blocks. The patient will then be required to practice what they have learned at home.

    Also known as: Questionnaires

  • ProcedureSham-NFB

    The intervention will consist of 12 training sessions at the hospital conducted with the assistance of a nurse. Each session will last approximately 40 minutes, with two resting EEG phases at the beginning and end of the session. The NFB procedure will consist of 6 training blocks of 75 seconds separated by 15-second rest blocks and 15-second baseline blocks. The patient will then be required to practice what they have learned at home.

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of NFB-FC training on seizure frequency

    Comparison to the NFB-sham training calculated in the pre-training period of reference

    Time frame: 3 months after the end of the training vs 3 months before training

Secondary outcomes

  1. To compare between groups the psychiatric impact (depression and anxiety)

    Changes between groups of psychiatric comorbidities, specifically depression: score of the NDDI-E (Neurological Disorders Depression Inventory for Epilepsy, 6 to 24, 24 meaning bad outcome) and anxiety: Score of GAD-7 (between 0 and 21, 21 meaning bad outcome)

    Time frame: 3-months after the end of the training

  2. To compare between groups the cognitive impact

    EpiTrack evaluation

    Time frame: One year after inclusion

  3. To compare between groups the quality of life

    QOLIE scale (Quality of Life in Epilepsy Inventory-Form 31, 0 to 100, 100 being the best outcome)

    Time frame: 3-months after the end of the training to the pre-training period

  4. To compare between groups the number of responders

    Patients showing a reduction in seizure frequency\>50%

    Time frame: 3-months after the end of the training

  5. To compare between groups the number of seizure-free patients

    Number of patients free of seizures

    Time frame: 3-months after the end of the training

  6. To compare between groups the change in seizure severity

    Score of seizure severity (NHS3, National Hospital Seizure Severity Scale, 1 to 27, 27 being the worst outcome)

    Time frame: 3-months after the end of the training

  7. The impact of transfer skills

    Use of the diary of seizures the Score of seizure severity

    Time frame: 6 weeks of applied learned strategies

  8. To assess, in the whole sample and per group (sham, active), correlations between FC changes and clinical outcomes

    Comparison of coherence values between the first recording (before the first session) and the last recording (after the last session) between responders and non-responders

    Time frame: At the end of the training and at 3 months after the end of the training

  9. To assess, in the whole sample and per group (sham, active), correlations between FC changes and clinical outcomes

    Comparison of coherence values between the first recording (before the first session) and the last recording (after the last session) between responders and non-responders

    Time frame: At 3 months after the end of the training

  10. To assess, in the whole sample and per group (sham, active), neurophysiological correlations, psychosocial factors and mental strategies and clinical outcomes.

    Score of mindfulness (FMI-fr); the Score of subjective cognitive state during NFB (NExT-Q), the Score of expectation and locus of control (Exp-LoC-Q),the Score of metacognition (Metacogn-IQ) and clinical outcome (seizure frequency, severity of seizures).

    Time frame: At 3 months after the end of the training

  11. To assess, in the whole sample and per group (sham, active), neurophysiological correlations, psychosocial factors and mental strategies and clinical outcomes.

    Score of mindfulness (FMI-fr); the Score of subjective cognitive state during NFB (NExT-Q), the Score of expectation and locus of control (Exp-LoC-Q),the Score of metacognition (Metacogn-IQ) and clinical outcome (seizure frequency, severity of seizures).

    Time frame: After each training sessions

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Sep 2028, 30 months later.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 30 months is below that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2025
First posted
Jan 21, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Oct 31, 2029
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07356661
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Jan 21, 2026

Study contacts

Angela Marchi
Contact
angela.marchi@ap-hm.fr
04 91 38 57 15 ext. 33
Fabrice Bartolomei
Contact
fabrice.bartolomei@ap-hm.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion